RLS/HS@Au/p53 alone modestly inhibited tumor growth by 53%, while the addition of SP141 (RLS/HS@Au/SP141/p53) resulted in a greater tumor inhibition of 89.3% by day 18 (Fig. 8b, c). Here, TP53 is linked to neoplasm.